Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity

BACKGROUND: HexaBody®-CD38 (GEN3014) is a hexamerization-enhanced human IgG1 that binds CD38 with high affinity. The E430G mutation in its Fc domain facilitates the natural process of antibody hexamer formation upon binding to the cell surface, resulting in increased binding of C1q and potentiated c...

Descripción completa

Detalles Bibliográficos
Autores principales: Hiemstra, Ida H., Santegoets, Kim C.M., Janmaat, Maarten L., De Goeij, Bart E.C.G., Ten Hagen, Wessel, van Dooremalen, Sanne, Boross, Peter, van den Brakel, Jeroen, Bosgra, Sieto, Andringa, Grietje, van Kessel-Welmers, Berris, Verzijl, Dennis, Hibbert, Richard G., Frerichs, Kristine A., Mutis, Tuna, van de Donk, Niels W.C.J., Ahmadi, Tahamtan, Satijn, David, Sasser, A. Kate, Breij, Esther C.W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320249/
https://www.ncbi.nlm.nih.gov/pubmed/37379657
http://dx.doi.org/10.1016/j.ebiom.2023.104663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320249/
https://www.ncbi.nlm.nih.gov/pubmed/37379657
http://dx.doi.org/10.1016/j.ebiom.2023.104663

Ejemplares similares